Sequel Announces First CGM Integration for its twiist AID System: Abbott's FreeStyle Libre 3 Plus Sensor

¹ "Derived AID Algorithm” means any AID Algorithm(s) based on or otherwise derived from the Tidepool Loop and used in the Twiist™Automated Insulin Delivery (AID) System as part of the Integrated System. Any Intellectual Property in addition to the Tidepool Loop that makes up part of the Derived AID Algorithm is owned by one or more of the Sequel Parties.

² Data on file. Abbott Diabetes Care, Inc. Based on retail and DME sales data for patient's last-filled prescription, by manufacturer.

³ Calculation based on a comparison of the following IFUs. The following reported 1 U/hr basal rate: The twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide, Sequel Med Tech (DKPI-09233-001-EN 1.7 2024- 10-21). Omnipod 5 Technical User Guide (PT-000941-AW Rev07 10/24), MiniMed 780G System User Guide (M036461C001_2 2023-02-24). iLet Bionic Pancreas System User Guide (LA000081_E 3-19-24). The following reported 2 U/hr basal rate: t:slim X2 Insulin Pump User Guide (AW-1011648_B 2023-Nov-09), Tandem Mobi System User Guide (AW-1012691_A 2023-Dec-07.)

⁴ The twiist Automated Insulin Delivery (AID) System Powered by Tidepool User Guide, Sequel Med Tech: DKPI-09233-001-EN 1.7 2024-10-21

Despite the proven benefits of AID systems-and American Diabetes Association's guidelines⁵ that suggest introducing AID systems for all people living with type 1 diabetes (T1D) -only about 60%⁶ of people with T1D currently utilize them. The hesitancy often stems from concerns about affordability, limited personalization options and a lack of trust in these systems⁶, indicating a significant need for new AID system solutions that address these challenges. Sequel's twiist AID System addresses these concerns by providing people living with T1D a management solution that they can access for $0 the first month and no more than $50 each month thereafter* through pharmacy channels. People with T1D can try twiist without the four-year commitment required by many traditional AID systems, and with the flexibility to manage their diabetes on their terms. Additionally, the twiist System gives users the confidence they will be alerted when they are not getting their expected insulin delivery⁴. With the integration of Abbott's FreeStyle Libre 3 Plus sensor, Sequel delivers a seamless solution for accessible, precise, and dependable diabetes management.

You can learn more about twiist and sign up for the latest updates regarding availability at www.twiist.com.

*To be eligible for the twiist Savings Program, participants must have commercial insurance and not be enrolled in programs that pay for prescriptions in whole or in part by Medicare, Medicaid or any other federal or state programs. It is only valid in the United States, and not valid for cash-paying participants, in Puerto Rico or other U.S. Territories, or where prohibited by law. The pay no more than $50 offer is applicable to most participants on commercial insurance, based on copay and coinsurance averages across all tiered cost sharing plan designs, but may not be applicable to participants on high-deductible plans who have not yet reached their deductible. Max benefit per month for covered claims is $200.

About Sequel Med Tech

Headquartered in Manchester, N.H., Sequel Med Tech, LLC is developing the next generation of transformative drug-delivery advancements. Sequel's approach is to look at disease management holistically to advance systems that make living with disease simpler and easier for all. Its FDA-cleared innovation, the twiist™ Automated Insulin Delivery (AID) System, integrates novel technologies to reimagine insulin delivery and sets a new standard for drug delivery. Co-founded by visionary Dean Kamen, serial entrepreneur Pablo Legorreta, seasoned medical device executive Bill Doyle and healthcare visionary Alan Lotvin, MD. Sequel is bringing the latest developments in science and technology to help drive more accessible drug delivery. For more information, visit sequelmedtech.com and twiist.com.

Important Safety Information Product for prescription only. For important safety information, please visit https://www.freestyle.abbott/us-en/safety-information.html.

Sequel Media Contact

Highwire PR

[email protected]

_______________

⁵ Diabetes Technology: Standards of Care in Diabetes-2025 | Diabetes Care | American Diabetes Association

⁶ December 2024, Seagrove Partners GlobeVIEW Forecast Model.